Table 1.
Clinical evaluation of anti-IGF-IR or anti-IGF1/2 mAbs in cancer patients
| Drug | Combination | Cancer type | Phase | Participants | Response | Ref. or trial ID |
|---|---|---|---|---|---|---|
| Ganitumab | None | Ewing sarcoma; desmoplastic small round cell tumors | 2 | 38 | PR, 16%; SD > 24 weeks: 49%. | [144] NCT00563680 |
| Ganitumab | Doxorubicin, etoposide or radiotherapy | Metastatic Ewing sarcoma | 3 | 330 | This trial is still ongoing. | NCT02306161 |
| Ganitumab | Palbciclib (CDK4/6 inhibitor) | Ewing sarcoma | 2 | 18 | This trial is still ongoing. | NCT04129151 |
| Ganitumab | Dasatinib | Rhabdomyosarcoma | 1/2 | 40 | This trial is still ongoing. | NCT03041701 |
| Ganitumab | Panitumumab | Colorectal cancer | 1/2 | 142 | ORR, 22%. No improvement, compared to panitumumab plus placebo. | [145] NCT00788957 |
| Ganitumab | None | Recurrent platinum-sensitive ovarian cancer | 2 | 61 | Objective response rate, 1.6% (95%CI 0-8.8%); CBR, 1.7% (95% CI, 0-8.9%); PFS, 1.94 months (95% CI 1.45-2.1 months). | NCT00719212 |
| Ganitumab | Gemcitabine | Metastatic pancreatic cancer | 3 | 640 | No improvement on OS. | [146] NCT01231347 |
| Ganitumab | Metformin | Breast cancer | 2 | Estimated enrollment of 4000 | This trial is still ongoing. | NCT01042379 |
| Figitumumab | None | Ewing sarcoma | 2 | 107 | PR, 14.02%; SD, 23.36%. | [147] NCT00560235 |
| Figitumumab | None | Ewing sarcoma | 1 | 16 | CR, 6.25%; PR, 6.25%; SD, 37.5%. | [148] NCT00474760 |
| Cixutumumab | None | Refractory solid tumors | 2 | 36 | PR, 8.33%; SD, 13.89%. | [149] |
| Cixutumumab | None | Previously treated advanced or metastatic rhabdomyosarcoma, leiomyosarcoma, adipocytic sarcoma, synovial sarcoma or Ewing family of tumors | 2 | 113 |
12-week PFR, 12% for rhabdomyosarcoma, 14% for leiomyosarcoma, 32% for adipocytic sarcoma, 18% for synovial sarcoma and 11% for Ewing family of tumors. Median PFS, 6.1 weeks for rhabdomyosarcoma, 6.0 weeks for leiomyosarcoma, 12.1 weeks for adipocytic sarcoma, 6.4 weeks for synovial sarcoma and 6.4 weeks for Ewing family of tumors. |
[150] |
| Cixutumumab | None | Metastatic melanoma of the eye | 2 | 18 | CR, 0; PR, 0; SD, 50%; PFS, 2.21 weeks (95% CI 0–23.2); OS, 59.71 weeks (95% CI 0–109.6) | NCT01413191 |
| Cixutumumab | Temsirolimus | Bone and soft tissue sarcoma | 2 | 159 | PR, 2.52%; SD, 61.64%; PD,35.85% | NCT01016015 |
| MK-0646 | Gemcitabine, Erlotinib | Advanced pancreatic carcinoma | 1/2 | 45 | PFS, 1.8 months (95% CI 1.8–9.7) for MK plus gemcitabine (arm A), 1.8 months (95% CI 1.7–5.5) for MK plus gemcitabine and erlotinib (arm B), and 1.9 months (95% CI 1.8–5.4) for gemcitabine and erlotinib (arm C); OS, 10.4 months (95% CI 3.9–18.9) for arm A, 7.1 months (95% CI 5.2–20.0) for arm B, and 5.7 months (95% CI 4.0–9.5) for arm C. | [151] NCT00769483 |
| Xentuzumab | Everolimus, exemestane | Breast cancer | 2 | 100 | This trial is still ongoing. | NCT03659136 |
| Xentuzumab | Everolimus, exemestane | Breast cancer | 1b/2 | 164 | This trial is still active. | NCT02123823 |
| Xentuzumab | None | Advanced solid tumors | 1 | 21 | This trial is still active. | NCT02145741 |
CR complete response, CBR clinical benefit rate, ORR overall response rate, OS overall survival, PFR progression-free survival rate. PFS progression-free survival, PR partial response, SD stable disease, Trial ID registered number at ClinicalTrials.gov